ranolazine has been researched along with Left Ventricular Hypertrophy in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aistrup, GL; Belardinelli, L; Beussink, L; Chirayil, N; El-Bizri, N; Gupta, DK; Kelly, JE; Misener, S; Mongkolrattanothai, T; Nahhas, A; Ng, J; O'Toole, MJ; Rajamani, S; Reddy, M; Shah, SJ; Shryock, JC; Singh, N; Wasserstrom, JA | 1 |
| Bargelli, V; Bartolucci, G; Belardinelli, L; Cerbai, E; Coppini, R; Crocini, C; Ferrantini, C; Gentile, F; Laurino, A; Mazzoni, L; Mugelli, A; Olivotto, I; Pioner, JM; Poggesi, C; Rotellini, M; Sacconi, L; Santini, L; Tardiff, J; Tesi, C | 1 |
| Chirkov, YY; Horowitz, JD; Kennedy, JA; Sverdlov, AL | 1 |
1 review(s) available for ranolazine and Left Ventricular Hypertrophy
| Article | Year |
|---|---|
Modulation of myocardial metabolism: an emerging therapeutic principle.
Topics: Acetanilides; Amiodarone; Cardiovascular Agents; Heart Failure; Humans; Hypertrophy, Left Ventricular; Myocardial Ischemia; Myocardial Perfusion Imaging; Myocardial Reperfusion; Myocardium; Perhexiline; Piperazines; Ranolazine; Trimetazidine; Vasodilator Agents | 2010 |
2 other study(ies) available for ranolazine and Left Ventricular Hypertrophy
| Article | Year |
|---|---|
Inhibition of the late sodium current slows t-tubule disruption during the progression of hypertensive heart disease in the rat.
Topics: Acetanilides; Animals; Calcium Channels, L-Type; Calcium Signaling; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Heart Failure; Hypertension; Hypertrophy, Left Ventricular; Male; Myocytes, Cardiac; NAV1.5 Voltage-Gated Sodium Channel; Piperazines; Ranolazine; Rats; Rats, Inbred SHR; Ryanodine Receptor Calcium Release Channel; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Sodium; Sodium Channel Blockers; Sodium Channels; Sodium-Calcium Exchanger; Time Factors; Ultrasonography | 2013 |
Ranolazine Prevents Phenotype Development in a Mouse Model of Hypertrophic Cardiomyopathy.
Topics: Animals; Blotting, Western; Calcium-Calmodulin-Dependent Protein Kinases; Cardiomyopathy, Hypertrophic; Disease Models, Animal; Echocardiography, Doppler; Excitation Contraction Coupling; Genetic Predisposition to Disease; Heart Rate; Hypertrophy, Left Ventricular; Magnetic Resonance Imaging; Male; Membrane Potentials; Mice, Inbred C57BL; Mice, Transgenic; Microscopy, Confocal; Mutation; Myocardial Contraction; Myocytes, Cardiac; Phenotype; Ranolazine; Sodium; Sodium Channel Blockers; Time Factors; Troponin T; Ventricular Dysfunction, Left; Ventricular Function, Left | 2017 |